ISPOR - POSA50 Cost-Effectiveness Analysis of Dupilumab for the Treatment of Severe Atopic Dermatitis in Adolescent and Children Patients in Italy

POSA50 Cost-Effectiveness Analysis of Dupilumab for the Treatment of Severe Atopic Dermatitis in Adolescent and Children Patients in Italy

Abstract

Authors

MP Pedone A Serra R Bitonti G Furneri

Full Text Cite This Article

Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now